Kochi Sims K, Killeen Kevin P, Ryan Una S
Avant Immunotherapeutics, Inc., Needham, MA 02494, USA.
Expert Rev Vaccines. 2003 Feb;2(1):31-43. doi: 10.1586/14760584.2.1.31.
The demand for new and improved vaccines against human diseases has continued unabated over the past century. While the need continues for traditional vaccines in areas such as infectious diseases, there is an increasing demand for new therapies in nontraditional areas, such as cancer treatment, bioterrorism and food safety. Prompted by these changes, there has been a renewed interest in the application and development of live, attenuated bacteria expressing foreign antigens as vaccines. The application of bacterial vector vaccines to human maladies has been studied most extensively in attenuted strains of Salmonella. Live, attenuated strains of Shigella, Listeria monocytogenes, Mycobacterium bovis-BCG and Vibrio cholerae provide unique alternatives in terms of antigen delivery and immune presentation, however and also show promise as potentially useful bacterial vectors.
在过去的一个世纪里，对新型和改良型人类疾病疫苗的需求一直有增无减。虽然在传染病等领域对传统疫苗仍有需求，但在癌症治疗、生物恐怖主义和食品安全等非传统领域对新疗法的需求也在不断增加。受这些变化的推动，人们对将表达外源抗原的减毒活细菌作为疫苗进行应用和开发重新产生了兴趣。细菌载体疫苗在人类疾病中的应用在减毒沙门氏菌菌株中得到了最广泛的研究。然而，减毒志贺氏菌、单核细胞增生李斯特氏菌、牛分枝杆菌卡介苗和霍乱弧菌的活菌株在抗原递送和免疫呈递方面提供了独特的选择，并且也显示出作为潜在有用细菌载体的前景。
